

HRA Meeting Atlanta - March 28, 2019

Collaborative Efforts to Advance Drug Discovery in IBD

Andrés Hurtado-Lorenzo, Ph.D.

SENIOR DIRECTOR OF TRANSLATIONAL RESEARCH

What will you learn today ?

**Collaborative mechanism
to advance
drug discovery
leveraging the
Foundation's research portfolio**

Outline

- Mission & Research Focus
- Collaborative effort to advance drug discovery
 - Rationale
 - Process
 - Outcomes
 - Take home message

Crohn's & Colitis Foundation

Largest Funder of IBD Research



Mission

To cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases

Research Focus


Overcome hurdles & accelerate research
to drive the continuum
from discovery to
optimal care




Discovery

Optimal Care


Therapeutics Discovery Continuum



Therapeutics Discovery Continuum



How to Bridge the Gap Between the Bench & Bedside



**Specialized Infrastructure
Pharmaceutical Scientists
Financial Resources**

3 Way Collaboration to Advance Drug Discovery



Strategy to Accelerate the Drug Discovery Continuum

Academic Research Portfolio

- Drug targets
- Targets biology
- Cell based assays
- Animal models



Drug targets


CROHN'S & COLITIS
FOUNDATION



**Project Selection
Funding
Oversight
Partnerships**

Drug Discovery Lab


- Drug discovery activities
- Chemical Libraries
- Pharma Scientists
- Candidate drugs
- Preclinical development




Drug candidates

3 Way Collaboration : Strategy

Partnering with a leading drug discovery organization



3 Way Collaboration : Process




Drug Target Selection Criteria:



Outcome and Timelines

- Conversations with Evotec started on Early 2017
- 2 Drug targets (2 different academic labs) - Dec 2017
- SOW (2 months) - Jan-Feb 2018
- Agreement Foundation – Academic Labs (9 months)
- 1 Agreement successfully executed - Nov 2018
- 1 unsuccessful agreement -
 - Road block – Tech Transfer Office – Inflexibility to accept value
 - PI did not work with TTO to demonstrate value
- Drug discovery activities started Feb, 2019

3 Way Collaboration to Advance Drug Discovery




Take Home Message

- 3 way collaboration
For Profit – Non Profit - Academia is possible
- Complex process – Persistence is key
- Takes longer than expected
- Tech Transfer Office inflexibility
may be the biggest roadblock
- Academic PI plays a critical role in demonstrating value to TTO
- Once the project starts, research advance:
 - Quickly
 - Adhered to a well defined multi-step process
 - Respecting rigorous timelines



Next Steps



***Collaborating to translate basic
research into effective drug
discovery and development
activities***

Thank you !